


**Pacific Blue™ anti-human HLA-DR**

**Catalog # / Size:** 2235080 / 100 µg  
**Clone:** LN3  
**Isotype:** Mouse IgG2b, κ  
**Immunogen:** human PBL  
**Reactivity:** Human  
**Preparation:** The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions. The solution is free of unconjugated Pacific Blue™ .  
**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.  
**Concentration:** 0.5



Human peripheral blood lymphocytes stained with LN3 Pacific Blue™

**Applications:**

**Applications:** Flow Cytometry  
**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.5 microg per 10<sup>6</sup> cells in 100 microL volume or 100 microL of whole blood. It is highly recommended that the reagent be titrated for optimal performance for each application.

\* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunohistochemical staining<sup>1</sup> of frozen sections and formalin-fixed paraffin-embedded sections<sup>1</sup>, and immunoprecipitation<sup>1</sup>.

**Application References:**  
 1. Marder RJ, *et al.* 1985. *Lab. Invest.* 52:497.  
 2. Norton AJ and Isaacson PG. 1987. *Am. J. Pathol.* 128:225.  
 3. Hua ZX, *et al.* 1998. *Hum. Pathol.* 29(12):1441.

**Description:** The LN3 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4<sup>+</sup> T cells.

**Antigen References:**  
 1. Levacher M, *et al.* 1990. *Clin. Exp. Immunol.* 81:177.  
 2. Terstappen L, *et al.* 1990. *J. Leuk. Biol.* 48:138.  
 3. Edwards J, *et al.* 1985. *J. Immunol.* 137:490.  
 4. van Es A, *et al.*